Please login to the form below

Not currently logged in

Cytheris gets €1.5m from OSEO

Biopharmaceutical company, Cytheris SA, has been awarded a loan worth €1.5m by OSEO
Biopharmaceutical company, Cytheris SA, has been awarded a loan worth €1.5m by OSEO, France's national agency for industrial innovation, to support its ongoing hepatitis C (HCV) clinical development programme.

Cytheris, which is focused on R&D of new therapies for immune modulation, will be given partial funding for the HVC programme of its lead product, recombinant human Interleukin-7 (r-hIL-7). This developmental product is a critical growth factor for immune T-cell recovery and enhancement.

Trials already conducted into r-hIL-7 in 75 patients across Europe, Canada and the US have shown its potential in expanding and protecting CD4+ and CD8+ T-cells. Cytheris is pushing forward with further international clinical studies of r-hIL-7 for use in diseases such as HCV, HIV and cancer.

Michel Morre, DVM, president and CEO of Cytheris, said: "The new OSEO support provided for our HCV study will partially cover the manufacturing, clinical studies and personnel costs associated with the programme as well as its expansion to include additional clinical sites in Asia."

Morre explained that OSEO funding has previously played a fundamental role in helping to set up the company. Cytheris has since fully repaid the loan to the OSEO.

15th July 2008


Featured jobs

Subscribe to our email news alerts


Add my company

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...